Avis Budget Group, Inc. (CAR)
CAR Q1 Earnings Miss on Higher Fleet Charges, Revenues Beat
Avis Budget's Q1 loss misses estimates as fleet charges stay high, but revenues beat and utilization hit a first-quarter record in more than 15 years.
Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Bristol Myers Squibb faces a major patent cliff but is well-equipped with a robust pipeline and significant CAR-T optionality. BMY trades at a discounted 9.4x forward P/E, reflecting patent cliff fears, yet offers 15-20% base case upside plus a 4.3% dividend yield. The 2026 catalyst stack includes Milvexian, Iberdomide, Cobenfy, and Sotyktu, any of which could drive a rerating to 10x-11x forward P/E.
A Wild Short Squeeze on Avis's Stock Takes Another Surprising Turn
The rental car company says a hedge-fund firm behind the big swings owes it money because of a niche trading rule.
Avis Budget Group, Inc. (CAR) Q1 2026 Earnings Call Transcript
Avis Budget Group, Inc. (CAR) Q1 2026 Earnings Call Transcript
Avis Budget (CAR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Avis Budget (CAR) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avis Plummets 12%, Hertz Drops 5% – What's Going On With Car Rental Stocks?
Shares of Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) are down roughly 12% in early Wednesday trading after the company released a disappointing Q1 2026 earnings report before market open (BMO).
Avis Budget Group (CAR) Reports Q1 Loss, Tops Revenue Estimates
Avis Budget Group (CAR) came out with a quarterly loss of $8.01 per share versus the Zacks Consensus Estimate of a loss of $6.83. This compares to a loss of $14.35 per share a year ago.
Legend Biotech: Undervalued Leader In The CAR-T Race
In my opinion, Legend Biotech Corporation is an attractive acquisition target for Johnson & Johnson. Carvykti, which they are jointly developing, is quickly catching up in sales with Darzalex, J&J's blockbuster for the treatment of multiple myeloma. So, sales of Carvykti reached $597 million in Q1, up 61.8% year-on-year, beating my 'best case' scenario by $15 million.
The Big 3: MU, NOW, CAR
Tim Biggam turns to three stocks he believes have overextended moves in recent trading session. To the upside: Micron (MU), which has rallied over 40% in the last month.
Avis Sinks 35%: Short Squeeze Fades as Dilution Risk Takes Center Stage
Shares of Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) are cratering in Thursday trading, with the stock last changing hands near $290 after closing Wednesday at $443.94.
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary catalyst; $126.9M cash runway extends into mid-2027.
Avis's stock has its worst day in 28 years, and what that means for its parabolic rally
Avis Budget's stock chart just sent some bearish signals to suggest a hard landing is in the works.
